ERDERA Clinical Trial Call – Annex IV. Guidelines for Canadian Applicants

1:1
This annex explains the specific eligibility, sponsorship, funding and application requirements for Canadian applicants in the ERDERA Clinical Trial Call.

This annex sets out the eligibility criteria, sponsor requirements, funds management rules, and application steps that apply to Canadian applicants requesting funding from the Canadian Institutes of Health Research (CIHR) within the ERDERA Clinical Trial Call(ECTC). It explains who is eligible, the requirement for an EU or Norwegian legal sponsor, how CIHR and ERDERA central funding are managed for Canadian partners, and the Stage 3 submission requirements for Canadian applicants.

blank

publication

Year of publication

2026

Author

European Rare Diseases Research Alliance (ERDERA)

You might also be interested in

ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
The NCL Foundation has opened the Rare-to-Common Neurodegeneration Impact Prize, a €200,000 research award supporting collaborative projects that connect CLN3 Batten disease research with more common neurodegenerative or age-related disorder
Feedback is open until 14 July 2026, giving stakeholders an early opportunity to comment during the preparation of a likely legislative proposal for a Council regulation.